149 related articles for article (PubMed ID: 38233440)
1. The natural breakthrough: phytochemicals as potent therapeutic agents against spinocerebellar ataxia type 3.
Naveed M; Ali N; Aziz T; Hanif N; Fatima M; Ali I; Alharbi M; Alasmari AF; Albekairi TH
Sci Rep; 2024 Jan; 14(1):1529. PubMed ID: 38233440
[TBL] [Abstract][Full Text] [Related]
2. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL
Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063
[TBL] [Abstract][Full Text] [Related]
4. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
5. Population genetics and new insight into range of CAG repeats of spinocerebellar ataxia type 3 in the Han Chinese population.
Gan SR; Ni W; Dong Y; Wang N; Wu ZY
PLoS One; 2015; 10(8):e0134405. PubMed ID: 26266536
[TBL] [Abstract][Full Text] [Related]
6. miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3.
Nobre RJ; Lobo DD; Henriques C; Duarte SP; Lopes SM; Silva AC; Lopes MM; Mariet F; Schwarz LK; Baatje MS; Ferreira V; Vallès A; Pereira de Almeida L; Evers MM; Toonen LJA
Nucleic Acid Ther; 2022 Jun; 32(3):194-205. PubMed ID: 34878314
[TBL] [Abstract][Full Text] [Related]
7. Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.
Ou Z; Luo M; Niu X; Chen Y; Xie Y; He W; Song B; Xian Y; Fan D; OuYang S; Sun X
Biomed Res Int; 2016; 2016():6701793. PubMed ID: 27847820
[TBL] [Abstract][Full Text] [Related]
8. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
Ashraf NS; Duarte-Silva S; Shaw ED; Maciel P; Paulson HL; Teixeira-Castro A; Costa MDC
Mol Neurobiol; 2019 May; 56(5):3690-3701. PubMed ID: 30187384
[TBL] [Abstract][Full Text] [Related]
9. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
10. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
Costa MDC; Ashraf NS; Fischer S; Yang Y; Schapka E; Joshi G; McQuade TJ; Dharia RM; Dulchavsky M; Ouyang M; Cook D; Sun D; Larsen MJ; Gestwicki JE; Todi SV; Ivanova MI; Paulson HL
Brain; 2016 Nov; 139(11):2891-2908. PubMed ID: 27645800
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
Krauss S; Nalavade R; Weber S; Carter K; Evert BO
Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
[TBL] [Abstract][Full Text] [Related]
12. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.
Prudencio M; Garcia-Moreno H; Jansen-West KR; Al-Shaikh RH; Gendron TF; Heckman MG; Spiegel MR; Carlomagno Y; Daughrity LM; Song Y; Dunmore JA; Byron N; Oskarsson B; Nicholson KA; Staff NP; Gorcenco S; Puschmann A; Lemos J; Januário C; LeDoux MS; Friedman JH; Polke J; Labrum R; Shakkottai V; McLoughlin HS; Paulson HL; Konno T; Onodera O; Ikeuchi T; Tada M; Kakita A; Fryer JD; Karremo C; Gomes I; Caviness JN; Pittelkow MR; Aasly J; Pfeiffer RF; Veerappan V; Eggenberger ER; Freeman WD; Huang JF; Uitti RJ; Wierenga KJ; Marin Collazo IV; Tipton PW; van Gerpen JA; van Blitterswijk M; Bu G; Wszolek ZK; Giunti P; Petrucelli L
Sci Transl Med; 2020 Oct; 12(566):. PubMed ID: 33087504
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
14. Toward understanding Machado-Joseph disease.
Costa Mdo C; Paulson HL
Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
[TBL] [Abstract][Full Text] [Related]
15. Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.
Bultum LE; Tolossa GB; Lee D
PLoS One; 2022; 17(7):e0270050. PubMed ID: 35895695
[TBL] [Abstract][Full Text] [Related]
16. Genetic Variation in ATXN3 (Ataxin-3) 3'UTR: Insights into the Downstream Regulatory Elements of the Causative Gene of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3.
Melo ARV; Raposo M; Ventura M; Martins S; Pavão S; Alonso I; Bettencourt C; Lima M
Cerebellum; 2023 Feb; 22(1):37-45. PubMed ID: 35034258
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
18. Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.
Bushart DD; Zalon AJ; Zhang H; Morrison LM; Guan Y; Paulson HL; Shakkottai VG; McLoughlin HS
Cerebellum; 2021 Feb; 20(1):41-53. PubMed ID: 32789747
[TBL] [Abstract][Full Text] [Related]
19. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
[TBL] [Abstract][Full Text] [Related]
20. Targeting Ubiquitin Proteasome Pathway with Traditional Chinese Medicine for Treatment of Spinocerebellar Ataxia Type 3.
Chen IC; Chang CN; Chen WL; Lin TH; Chao CY; Lin CH; Lin HY; Cheng ML; Chiang MC; Lin JY; Wu YR; Lee-Chen GJ; Chen CM
Am J Chin Med; 2019; 47(1):63-95. PubMed ID: 30612452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]